Mohamed ALI Alabiad
Zagazig, Sharqia Province, 14150, Egypt
NCT Number: NCT05198141
The utilization of letrozole at a daily dose of 10 mg for medical treatment of ectopic pregnancy considerably has a high success rate without imposing any serious side effects compared to daily 5mg letrozole.
Looking for future studies?
Notify Me19 year–35 year
Female
Interventional
Phase 4
Zagazig, Sharqia Province, 14150, Egypt
Letrozole, an aromatase inhibitor, has recently been introduced as favorable medical treatment for ectopic pregnancy. We aimed at evaluating the effects of different doses of letrozole for induction of abortion Sixty patients with undisturbed ectopic pregnancy were classified into three equal groups. Group I: The control group that contained women who were undergoing laparoscopic salpingectomy, Group II: Patients who received letrozole (5 mg d-1) for 10 d, and Group III: Patients who received letrozole (10 mg d-1) for 10 d. After that, the human chorionic gonadotropin (β-hCG) levels were determined for the first day and after 11 d of treating. letrozole (10 mg d-1) markedly reduced the receptors of estrogen and progesterone, and subsequent vascular endothelial growth factor signals, resulting in marked apoptosis in the placenta tissue. The utilization of letrozole at a dose of 10 mg d-1 for inducement of abortion typically results in a substantial high-successful rate without any severe side effects.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
GI: Patients who were undergoing laparoscopic salpingectomy GII: patients who medically treated with 5 mg d-1 of letrozole using two tablets (2.5 mg of Femara) every day for 10 d GIII patients who medically treated with 10 mg d-1 of letrozole using four tablets (2.5 mg of Femara) every day for 10 d (group III)
Other names: Femara
laparoscopic salpingectomy
Time frame: The β-hCG levels were assessed on the 1st of treatment
A quantitative human chorionic gonadotropin
Time frame: The β-hCG levels were assessed on the 11th day of treatment
A quantitative human chorionic gonadotropin
Time frame: Assessed on the 1st day of treatment
Complete blood count
Time frame: Assessed on the 1st and 11th day of treatment
Liver enzyme
Time frame: Assessed on the 1st and 11th day of treatment
Liver enzyme
Time frame: Assessed on the 1st and 11th day of treatment
Renal function test
Time frame: Assessed on the 1st and 11th day of treatment
Renal function test
Time frame: Assessed on the 11th day of treatment
Complete blood count
Time frame: Assessed on the 11th day of treatment
Liver enzyme
Time frame: Assessed on the 11th day of treatment
Liver enzyme
Time frame: Assessed on the 11th day of treatment
Renal function test
Time frame: Assessed on the 11th day of treatment
Renal function test
Zagazig University
Other Gov
Evaluation of Different Doses of Aromatase Inhibitor Letrozole for the Treatment of Ectopic Pregnancy
Acronym: letrezole
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06559280
Ectopic Pregnancy, Female Urogenital Diseases and Pregnancy Complications
Fuzhou, Fujian, China
View Trial DetailsNCT06504082
Ectopic Pregnancy, Female Urogenital Diseases and Pregnancy Complications
Van, Tuşba, Turkey (Türkiye)
View Trial DetailsNCT04739956
Anxiety, Anxiety Disorders
London, United Kingdom
View Trial DetailsNCT05039853
Abortion, Spontaneous, Ectopic Pregnancy
London, United Kingdom
View Trial Details